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Objectives: Patients with COPD are at risk for osteoporosis-related vertebral compression frac-
tures (VCF) which predispose tomore fractures andworsening pulmonary function. Our objectives
were to: 1 document VCF prevalence in COPD patients; and 2 determine the independent corre-
lates of VCF.
Methods: From2004e2006,weprospectively recruited consecutive consentingCOPDpatients pre-
senting with acute exacerbation at three Canadian Emergency Departments (ED). We collected
clinical and pulmonary function data. Primary outcome was radiologist documented VCF on chest
radiograph. Multivariable logistic regression was used for all adjusted analyses.
Results: Overall, 245 patientswere studied; 37%were75 years and 44%werewomen. Prevalence
of VCF documented by chest radiograph was 22 of 245 (9%; 95%CI 6e13%). Almost half (10 of 22
[43%])ofVCFpatientswerenot treated forosteoporosisandall 10 receivedoral steroids.Compared
to patients without fractures, thosewith VCFwere older (pZ 0.014), had COPD of longer duration
(pZ 0.09) and greater severity (mean FEV1 0.9 vs 1.1 L; pZ 0.05), and had lower bodymass index
[BMI] (median 26 vs 28; pZ 0.01). Across BMI quartiles (from heaviest [median 37] to lightest
[median 21]) the prevalence of VCF progressively increased (2%, 8%, 10%, 21%; p< 0.001). In anal-
yses adjusted for age, sex, andCOPDduration, the only independent correlate ofVCFwas BMI: VCF
increased as BMI decreased from heaviest (ORZ 1) to lightest (ORZ 11.0) quartiles (pZ 0.025).ts from the Canadian Association of Emergency Physicians Research Consortium. SRM receives salary
undation for Medical Research (Health Scholar); BHR holds a Canada Research Chair in Emergency
0 407 1399; fax: þ1 780 407 3132.
alberta.ca (S.R. Majumdar).
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Vertebral fracture in patients with COPD 261Conclusions: Almost one-tenth of COPD patients presenting with acute exacerbation have chest
radiographs documenting VCF. About half of patients with VCF were not treated for osteoporosis,
but all were started on oral steroids. Our findings suggest chest radiograph reports may represent
an important case-finding tool for VCF, particularly in underweight patients with COPD.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Both chronic obstructive pulmonary disease (COPD) and
osteoporosis are common, affecting an estimated 10 million 1
and 44 million Americans 2 respectively. With the population
aging, the prevalence of both diseases is on the rise,2,3 and
COPD patients are at particular risk of developing osteopo-
rosis.4,5 Indeed, COPD and osteoporosis share several risk
factors including older age and smoking.1,3,6 Furthermore,
advanced COPD is associated with regular systemic cortico-
steroid use, chronic inflammation and low body weight, all of
which predispose to osteoporosis.4,7e9 The only clinical
sequela of osteoporosis is fracture, the most common of
which is the vertebral compression fracture.10 In addition to
pain and height loss, osteoporosis-related vertebral
compression fractures (VCFs) can lead to kyphosis that
directly impairs pulmonary function e both in terms of
reduced vital capacity (9% decrease in vital capacity per
fracture) and perhaps even increased airflow obstruction.11
This is concerning in patients with COPD who often already
have compromised pulmonary status.
Regrettably, VCFs are rarely diagnosed as 60e70% are
asymptomatic and thus escape clinical detection.12 Never-
theless, patients with osteoporosis-related VCFs have at
least a 5-fold increased risk of another vertebral fracture
and a 3-fold increased risk of hip fracture.13 As a result, it is
important to target patients with VCFs because appropriate
treatment with a number of approved agents reduces the
risk of future fracture by about 50%.14 Although population-
screening for osteoporosis-related VCF is not recom-
mended,6 a potentially valuable case-finding tool in
patients with COPD might be recognition of ‘‘incidental’’
vertebral deformities documented by chest radiographs
undertaken during an acute exacerbation. Because most
VCF involve the mid-thoracic (T7-T8) spine and the thoraco-
lumbar junction (T12-L1), and because these regions can be
quite adequately visualized with standard chest radio-
graphs, about 80e90% of VCF could potentially be identi-
fied.15 In fact, this is one of the reasons that the chest
radiograph is such a well validated method to identify
previously unrecognized VCFs.15,16 Studies performed at
our center have demonstrated that at least 60% of clinically
important vertebral fractures are recognized and reported
on chest radiographs and that board-certified radiologists
have a specificity for documenting fractures of 100%.15,16
Since most patients with COPD will, by necessity, receive
multiple chest radiographs over time, these radiographs
might be useful for detecting VCFs. The potential yield of
this approach has not been well-described.
Previous reports suggest that 10e30% of COPD patients
have clinically important moderate-to-severe grade VCFs
found using various radiographic imaging modalities.13,16e21These previous studies, however, are limited by small
sample size,13,16,19,20 lack of clinical data,16 poor or inade-
quately documented reliability of vertebral fracture identi-
fication,17 or analyses of populations with limited
generalizability.13,17,18,20,21 Therefore, we undertook
a prospective cohort study of consecutive patients with
COPD exacerbation visiting the Emergency Department (ED)
with two main objectives: 1 to describe the prevalence of
chest radiograph documented VCFs; and 2 to determine the
independent correlates of vertebral fracture, with attention
to easily measured historical (i.e., COPD duration, cortico-
steroid use) and clinical (i.e., weight, spirometry) data.Methods
Subjects and setting
From 2004 to 2006, we conducted a 3-site prospective
cohort study of consecutive consenting patients with acute
exacerbation of COPD seen in the ED in Edmonton, Alberta,
Canada. We previously established the accuracy and reli-
ability of vertebral fracture documentation on chest
radiograph of our 3 site’s radiologists.15,16 The study EDs
represent about half the emergency care capacity for the
region which has about 1000 primary care physicians and
provides care for one million people with universal health
care coverage. Inclusion criteria were: age greater than 35
years; physician-diagnosis of chronic bronchitis, emphy-
sema, or COPD; treated in the ED for an acute COPD
exacerbation that met at least one of three validated
criteria 22; 15 or more pack-years of smoking; ability to
communicate in English; and provision of written informed
consent. We screened 1095 potentially eligible patients at
our three study EDs, and excluded 161 patients because
they did not meet all inclusion criteria, and excluded
another 468 patients because they had reasons for acute
presentation that were not related to COPD (i.e., asthma,
bronchiectasis, pulmonary fibrosis or radiographic evidence
of pneumonia or heart failure). The 245 study patients were
cared for by board-certified Emergency Medicine special-
ists, interviewed by research personnel (registered nurses),
underwent spirometry, and had a standard posteroanterior
and lateral chest radiographs interpreted by a board-
certified radiologist. The study received ethics approval
from the University of Alberta.
Outcomes
Our dependent binary variable of interest was the presence
or absence of a recognized and board-certified radiologist
documented VCF on chest radiograph.15,16 A fracture was
262 S.R. Majumdar et al.considered to be present if there was any mention of
vertebral fracture, deformity, compression, wedging, or
loss of height reported in the body or summary of the
official radiograph report.15,16 VCFs present when these
terms are used for reporting fall into the grade 2
(moderate) or grade 3 (severe) category,23 and are widely
considered to be ‘‘clinically important’’ 15,16,21,23 The
reliability and validity of this method of fracture recogni-
tion on chest radiograph, compared with both a reference
standard osteoporosis expert radiologist using semi-quan-
titative methods as well as automated quantitative digital
morphometry, has been extensively documented at our
sites.15,16 In summary, the true positive rate of reporting by
our radiologists is 60% (95%CI 48e71) with moderate inter-
rater agreement (kappaZ 0.64, 95%CI 0.53e0.75);
however, specificity for reporting of moderate-to-severe
VCFs is 100%.15,16
Other measurements
We prospectively collected general information on socio-
demographic (e.g., age, sex, education) and clinical (e.g.,
smoking status, self-reported comorbidities, medications)
characteristics. Single item health status (in the week
prior to illness) was asked of each patient. In terms of
COPD, we ascertained disease duration, current and past
inhaled and oral treatments, and collected physical
measures that included height, weight, and pulmonary
function tests determined using MicroLoop Spirometers
(Spida 5 software, MicroMedical). For the latter, we
report the last (post-bronchodilator) measurements of
FEV1, FVC, and PEF obtained in the ED before discharge
home or admission to hospital. All data were obtained
through structured interviews and medical record
abstraction by research personnel masked to all osteopo-
rosis-related hypotheses.
Analysis
Data are presented as numbers and proportions (%), means
with standard deviations (SD), or medians with interquartile
ranges (IQR), as appropriate. For univariable analyses we
used chi-square tests, t-tests or Mann-Whitney U tests.
Because of relatively few outcomes (nZ 22), multivariable
logistic regression modeling strategies were undertaken
both purposefully and parsimoniously e acknowledging that
we could not assess more than four or five potentially
independent variables if we wanted to avoid over-fitting.
We forced age and sex into our models, and then consid-
ered for inclusion covariates based on a review of the
literature, biologic plausibility, association (p< 0.2) with
the presence of a vertebral fracture on univariable analysis,
or if confounding (10% or greater change in beta-estimates
of any included parameter) was present. All first-order
interaction terms were tested; none were statistically
significant (p< 0.1) and so none are included in the final
models. We report adjusted odds ratios (OR) with their 95%
confidence intervals (CI), and describe the overall model
goodness of fit using the c-statistic (a measure akin to the
area under the curve). All analyses were performed using
Stata Statistical Software, Release 10 (College Station, TX:
Stata Corporation).Results
Overall, 37% of patients were 75 years of age or older, 44%
were women, and 7% were non-white. About half (54%)
reported fair or poor health and the majority (69%) had one
or more comorbidities unrelated to COPD (Table 1). In
terms of COPD, 30% had a 10 year or longer duration of
disease, 23% had very severe disease (defined by
a FEV1< 30% predicted), 37% required admission to
hospital, and 86% were already treated with oral cortico-
steroids (Table 2). The overall prevalence of one or more
VCFs documented by chest radiograph was 22 of 245 (9%,
95%CI 6e13%).
Potential correlates of vertebral fracture
In general, patients with VCF were older, sicker, and more
likely to have a diagnosis of osteoporosis (57% vs 12% of
those without fracture, p< 0.001). Ten of 22 (43%) patients
with COPD and documented VCF were not treated for
osteoporosis and all 10 of these patients were discharged
from the ED with oral corticosteroid therapy. Table 1
provides general patient characteristics stratified by the
presence or absence of VCF. In terms of their COPD,
patients with VCF tended to have more severe disease
based on history or spirometry. For example, 45% had 10 or
more years of disease compared with 28% of patients
without a fracture (pZ 0.093). Also, results of all pulmo-
nary function tests tended to be worse among patients with
VCF; for instance, mean FEV1 was 0.9 (SD 0.4) L vs 1.1 (SD
0.6) L for those without fracture (pZ 0.055). Table 2
provides measures of COPD severity and treatments strat-
ified by presence of VCF.
There was a particularly noteworthy relationship seen
between weight and VCF. Patients with fracture weighed
less, whether considering their weight (median 67 kg vs
80 kg, pZ 0.033) or body mass index [BMI] (median 26 vs
28, pZ 0.010). To explore this association in further detail,
we grouped patients into quartiles according to their BMI
and arranged the data from heaviest quartile (median
BMIZ 37) vs BMIZ 30 vs BMIZ 26 vs BMIZ 21 (lightest
quartile). The Fig. 1 illustrates the strong and graded
increased risk for VCF with decreasing levels of BMI
(p< 0.001 for trend).
Multivariable analysis
In models adjusted for age, sex, and duration of COPD, the
only independent correlate of the presence of a docu-
mented VCF was BMI (Table 3). None of the measures of
pulmonary function, such as FEV1 or PEF, remained signifi-
cant in models that were adjusted for age, sex, and COPD
duration nor did they confound the association between
fracture and BMI (data not shown). Compared with the
heaviest quartile of patients, those who were most under-
weight (lightest quartile, median BMIZ 21) had a signifi-
cant 11-fold increased risk of VCF (2% vs 16% prevalence,
adjusted odds ratio 11.0, 95%CI 1.3e90.7, pZ 0.025). The
c-statistic for our final multivariable model was 0.71. The
relationship between weight and VCF was present regard-
less of how it was classified. For example, simply
Table 1 Description of 245 Patients Treated in the Emergency Department for an Acute Exacerbation of COPD, According to
the Presence or Absence of Documented Moderate-to-Severe Vertebral Fractures.
Characteristics With moderate-to-severe





Age, median years (IQR) 76 (68e73) 70 (61e77) 0.014
Age> 75 years 12 (55) 78 (35) 0.094
Female 8 (36) 100 (45) 0.4
White 22 (100) 207 (93) 0.2
Married 9 (41) 106 (48) 0.6
High school completed 3 (14) 46 (21) 0.6
Self-Reported Health
Fair or Poor 13 (59) 119 (53) 0.8
Comorbidities
Hypertension 10 (45) 105 (47) 0.9
Coronary disease 6 (27) 54 (24) 0.8
Heart failure 4 (18) 28 (13) 0.5
Diabetes 3 (14) 35 (16) 1.0
Osteoporosis 13 (59) 42 (19) <0.001
No other comorbidities 6 (27) 70 (31) 0.9
Medications
Diuretics (loop or thiazide) 11 (50) 57 (26) 0.015
Thyroid replacement 3 (14) 28 (13) 0.8
Anticonvulsants 0 3 (1) e
Estrogen replacement 0 9 (4) e
Bisphosphonates 12 (57) 27 (12) <0.001
Calcium supplements 6 (27) 24 (11) 0.024
Vitamin-D supplements 6 (27) 13 (6) <0.001
No other medications 6 (27) 118 (53) 0.028
IQR, denotes interquartile range; COPD, chronic obstructive pulmonary disease.
Vertebral fracture in patients with COPD 263considering BMI as a dichotomous variable (below vs above
the average of 28) demonstrated the same relationship:
those below average BMI had an adjusted odds ratio for VCF
of 8.6 (95%CI 1.8e41.6, pZ 0.007). Even considering
weight as a continuous measure, the adjusted odds ratio for
VCF was 0.96 (95%CI 0.94e0.99, pZ 0.012) per kg, roughly
a 4% reduction in fracture for each additional kg of weight.Discussion
In our study of patients presenting to the ED with an acute
exacerbation of COPD, we found almost one in ten had
a clinically important moderate-to-severe VCF documented
on their official chest radiograph report. About half (43%) of
the patients with VCF were not receiving treatment for
osteoporosis but all of these patients received oral corti-
costeroids in the ED. Patients with VCFs were older, had
more comorbidity, and seemed to have more severe COPD
(based on history or spirometry) than those without frac-
ture. Of note, patients with fracture weighed significantly
less than patients without fracture, and BMI was the only
independent correlate of VCF in multivariable analyses e
compared to the heaviest quartile of patients, those in the
lightest quartile (median BMI 21) had an adjusted 11-fold
increased risk.
Our reported 9% prevalence of vertebral fracture in
patients with COPD exacerbation is in keeping with previousreports that suggest a prevalence of clinically important
VCF ranging from 10e30%.13,16e21 Vertebral fracture prev-
alences at the lower end of this range were reported in
studies that considered male COPD outpatients who had
never used large doses of oral corticosteroids 18 while
prevalences at the higher end of this range included post-
menopausal women and patients exposed to large cumu-
lative doses of corticosteroids.18,20,21 In addition, we
identified VCFs using the official chest radiograph report
while several previous studies used study radiologists or
automated digital morphometry to independently re-
review and then identify fractures of all degrees (i.e., mild,
moderate, and severe) 13,16e21; these latter methods
consistently demonstrate higher fracture prevalence
because of inclusion of much less severe fractures and
better recognition of moderate and severe fractures and
confirm systematic under-reporting in routine chest radio-
graph reports.13,15e17 Using the previously documented
100% specificity and 40% false-negative reporting rate at
our center,15,16 we estimate that the prevalence of clini-
cally important VCFs in our cohort of COPD patients is
approximately 15% e thereby bringing our results in line
with previous estimates.13,16e21
The other noteworthy finding in our study was the
striking association between low body weight and vertebral
fractures. There are two plausible explanations. First, low
body weight in and of itself is a well-established risk factor
for low bone mineral density.9,24e27 Patients with COPD are
Table 2 Clinical and Pulmonary Function Measures of COPD Severity According to Presence or Absence of Documented
Moderate-to-Severe Vertebral Fracture.
Characteristics With moderate-to-severe





COPD, median years (IQR) 12 (5e16) 6 (3e12) 0.16
COPD duration> 10 years 10 (45) 63 (28) 0.093
Current Smoker 4 (19) 92 (42) 0.060
Pack-years, median (IQR) 35 (22e51) 40 (25e55) 0.6
Weight, median kg (IQR) 67 (60e88) 80 (68e95) 0.033
Body mass index, median kg/m2 (IQR) 26 (21e29) 28 (24e33) 0.010
COPD Management
Discharged on oral steroids 20 (91) 191 (86) 0.5
Treatments at presentation
Oral steroids 14 (64) 139 (62) 0.8
Inhaled steroids 5 (23) 65 (29) 0.6
Short-acting beta-agonist 17 (77) 161 (72) 0.7
Long-acting beta-agonist 13 (59) 100 (48) 0.14
Inhaled anticholinergic 17 (77) 122 (55) 0.019
Theophylline 5 (23) 24 (11) 0.077
Admitted to hospital 12 (55) 79 (35) 0.077
Pulmonary Function Testsþ
FEV1, mean L (SD) 0.9 (0.4) 1.1 (0.6) 0.055
FEV1, % predicted (SD) 38 (15) 44 (20) 0.11
FEV1/FVC, ratio (SD) 50 (14) 57 (19) 0.061
PEF, mean L/min (SD) 124 (74) 170 (102) 0.042
PEF, % predicted (SD) 31 (16) 43 (21) 0.016
Very severe (FEV1< 30%) 6 (27) 50 (22) 0.6
þLast post-bronchodilator measurement performed in the Emergency Department. COPD, denotes chronic obstructive pulmonary
disease; IQR, interquartile range; FEV1, Forced expiratory volume at first second; FVC, forced vital capacity; FEV1/FVC, Forced expi-
ratory volume first second/forced vital capacity; PEF, peak expiratory flow.
264 S.R. Majumdar et al.predisposed to low body weight for a variety of reasons
including malnutrition, depression and hyper-catabolism
related to increased energy costs of breathing, tissue
hypoxia, use of beta-agonists, and chronic systemic
inflammation.5,7,28 Alternately, it may just be that low body
weight is an excellent proxy measure for severity of COPD.
Studies have shown a direct association between low bone
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Figure 1 Prevalence of Moderate-to-Severe Vertebral Frac-
tures in Patients with COPD According to Body Mass Index.spirometry,29e32 but none of these examined the relation-
ship between vertebral fracture and disease severity.
The few studies that have examined the association
between vertebral fracture and severity of COPD have had
conflicting results.13,18,19,21,33 This may be in part related to
how ‘‘severity’’ is defined.13,18,19,21 For example, patients’
measured heights are often used to calculate the percent
predicted values for pulmonary function tests, and use of
measured heights will systematically under-estimate COPDTable 3 Independent Correlates of the Presence of
a Moderate-to-Severe Vertebral Fracture in Patients with
COPD Exacerbation (Multivariable Logistic Regression).
Variable Adjusted odds ratio
(95% Confidence Interval)
P-value
Age> 75 years 1.5 (0e3.9) 0.4
Female 1.1 (0.4e3.1) 0.8
COPD duration> 10 years 1.9 (0.7e5.2) 0.2
Quartiles of Body
Mass Index
1 (median BMIZ 37) 1.0 (reference group) e
2 (median BMIZ 30) 4.6 (0.5e41.2) 0.17
3 (median BMIZ 26) 5.6 (0.6e48.9) 0.12
4 (median BMIZ 21) 11.0 (1.3e90.7) 0.025
Vertebral fracture in patients with COPD 265severity in patients with vertebral fractures, height loss,
and kyphosis.11 Using arm span corrects this bias and has
been recommended.11 If we (and others 13,18,19,21) had used
arm span for determining predicted values, a stronger and
more robust association between COPD severity and
vertebral fractures might have been detected. In addition,
our measures of pulmonary function were obtained soon
after management of an acute exacerbation, and may not
reflect a true ‘‘baseline’’ of COPD severity. For our
purposes, the mechanism for the association between low
body weight and COPD severity and fracture is perhaps less
important than the fact that it is robust and can be applied
in the clinical setting.
This study has several limitations that merit consider-
ation. First, we did not undertake dedicated spinal radio-
graphs or re-review chest radiographs to determine the
prevalence of vertebral fracture. However, it should be
acknowledged our objective was to examine the issue using
the data that are already available to any physician that is
managing COPD. Thus our use of chest radiograph reports
might instead be considered a strength.
Second, we had no measures of bone mineral density.
Nevertheless, more than 90e95% of patients over the age of
60 years with a VCF have low bone mass 34 and current
guidelines suggest that osteoporosis treatment could be
initiated without measurement of bone mineral density.6
That said, bone mineral density testing near the time that
treatment is started may still be useful to document the
severity of osteoporosis, to monitor response to treatment
over time, and even to ensure medication adherence.
Third, concerns about the absence of bone mineral
density measurements do not acknowledge the fact that
the COPD patients with documented fracture in our study
were almost universally started on moderate-to-high doses
of oral corticosteroids (the standard regimen at our center
is 50 mg of prednisone per exacerbation for 10e14 days, for
a total dose >0.5 g). It is a weakness of our study that we
had no way of determining the total or lifetime cumulative
dose of corticosteroids received prior to presentation,
another risk factor for osteoporosis.
Fourth, we did not collect some specific osteoporosis-
related data, such as remote use of bone-sparing agents
like the bisphosphonates, past history of non-vertebral
fractures, vitamin-D sufficiency, hypogonadism, family
history, or measures of physical activity. One could imagine
how several of these risk factors might co-exist and lead to
very heightened risk for osteoporosis. For example,
consider a 65-year old, white, underweight, post-meno-
pausal woman with COPD who still smokes and has very
limited exercise capacity e not an uncommon scenario in
clinic, but an almost incalculable risk for osteoporosis-
related fracture.
Finally, in terms of wider applicability of our results, we
note that our patients were selected at the time of COPD
exacerbation and were volunteers willing to participate in
an observational study suggesting they might be somewhat
‘‘healthier’’ than the general population seeking care in
the ED, thus under-estimating the prevalence of VCF in
patients with COPD.
Accepting the limitations of our work, the findings may
still have important potential implications for practicing
clinicians. First, physicians who regularly treat patientswith COPD exacerbations should keep in mind the results of
chest radiographs and the need for osteoporosis manage-
ment when considering the decision to prescribe oral
corticosteroids. Second, since other fractures have been
successfully targeted in the ED and had interventions
directed at them in the community to improve screening
and treatment of osteoporosis,35 perhaps interventions
could be developed and tested to address the problem of
unrecognized and untreated VCF in COPD patients.Conclusions
Almost one-tenth of patients with COPD exacerbation have
VCF recognized and documented by chest radiograph.
About half of these patients were not receiving treatment
for osteoporosis, and yet all of these patients were
prescribed oral corticosteroids putting them at risk for
more fractures and perhaps additional compromise of
pulmonary function. Our findings suggest that the chest
radiograph may be an important case-finding tool for
vertebral compression fractures, particularly for those
COPD patients who are underweight.Conflicts of interest
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